Energy Bill Health Risks: “One Big Beautiful Bill” Concerns
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death - in adults...
- The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.
- The SELECT trial specifically enrolled individuals with a body mass index (BMI) of 27 or higher *and* established cardiovascular disease, such as a history of heart attack, stroke,...
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
Table of Contents
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated notable weight loss, this benefit was accompanied by a concerning signal regarding cardiovascular safety.
The Data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk. Importantly, the weight loss achieved with semaglutide – an average of approximately 15% of initial body weight – did not appear to offset this cardiovascular risk.
| Event | Semaglutide Group (%) | Placebo Group (%) |
|---|---|---|
| Cardiovascular Death | 1.5% | 1.2% |
| Nonfatal Stroke | 1.7% | 1.3% |
| Nonfatal Myocardial Infarction (Heart Attack) | 3.7% | 2.9% |
| Major Adverse Cardiovascular Events (MACE) | 6.5% | 4.9% |
who is Affected? Understanding the Patient Population
The SELECT trial specifically enrolled individuals with a body mass index (BMI) of 27 or higher *and* established cardiovascular disease, such as a history of heart attack, stroke, or peripheral artery disease. This is a crucial detail. The findings do *not* necessarily apply to individuals with obesity who do not have pre-existing heart conditions. However, given the prevalence of cardiovascular disease, a significant portion of the population seeking weight loss treatment may fall into this higher-risk category.
It’s also significant to note that the average age of participants was 61, and a substantial proportion had type 2 diabetes.This raises questions about whether the observed cardiovascular risk is solely attributable to semaglutide or is influenced by the interplay of obesity, diabetes, and pre-existing heart disease.
What Does This Mean? Implications for Patients and physicians
These findings are a wake-up call. While medications like Ozempic have been lauded for their effectiveness in promoting weight loss,this trial underscores the importance of carefully considering the potential risks,especially in patients with established cardiovascular disease. A blanket approach to prescribing these medications is no longer justifiable.
Patients currently taking semaglutide who have pre-existing heart conditions should discuss these findings with their healthcare provider. A personalized risk-benefit assessment is essential. Physicians should be more diligent in screening patients for cardiovascular risk factors *before* initiating semaglutide therapy.
Timeline of Events & Regulatory Response
August 17,2023: Results
Worth a look